Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05758077Not ApplicableRecruiting

Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury

Role: lead

NCT03836482Not ApplicableRecruiting

Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

Role: lead

NCT06517810Recruiting

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

Role: lead

NCT01072682Not ApplicableCompleted

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

Role: lead

NCT04395911Not ApplicableCompleted

Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections

Role: lead

NCT01400893Not ApplicableTerminated

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

Role: lead

NCT04537975Not ApplicableWithdrawn

C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19

Role: lead

All 7 trials loaded